Pune: A teacher who rented a building to ensure 2,000 girls did not drop out of school and started distributing sanitary ...

Pune: A teacher who rented a building to ensure 2,000 girls did not drop out of school and started distributing sanitary napkins to counter uterine ca.

NEW YORK – GSK will roll out its anti-PD-1 therapy Jemperli (dostarlimab) for certain endometrial cancer patients and its PARP inhibitor Zejula (niraparib) for ovarian cancer patients in India.

GSK India has launched Jemperli and Zejula for gynaecological cancers, marking its return to oncology a decade after ...

GSK today announced the availability of its much-awaited advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in ...

Don’t Miss These Signs Cancer is one of the leading causes of death worldwide, and many people often overlook or dismiss ...

Bhushan Akshikar, Managing Director of GSK India, said the company is committed to making these therapies accessible through a tiered pricing strategy and a comprehensive patient support program ...

Endometrial cancer risk is rising, especially among premenopausal women, with diet and lifestyle factors playing a central ...

GlaxoSmithKline Pharmaceuticals said it is bringing in Jemperli and Zejula to India, marking its re-entry into the cancer ...

At around 2.14 PM, GSK Pharma was trading 0.28% higher at ₹2,806.70 per piece, against the previous close of ₹2,798.80 on NSE.

GlaxoSmithKline Pharmaceuticals on Monday said it has made a foray into the oncology segment, bringing precision therapies ...

GlaxoSmithKline Pharmaceuticals has launched Jemperli and Zejula in India, pioneering precision therapies for gynaecological ...